Toripalimab plus radiation before surgery for stage II–IIIA lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies whether adding toripalimab (an immunotherapy medicine) to radiation can improve outcomes for people with operable stage II to IIIA non-small cell lung cancer. It’s designed for cancers that can be fully removed with surgery, and it aims to see if this combination helps more than radiation alone/standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- Your lung cancer has been confirmed by pathology (biopsy or surgery sample).
- Your cancer stage is operable stage II–IIIA (or T3N1M0) with no distant spread on CT or PET/CT.
- Your tumor does NOT have common driver gene changes in EGFR, ALK, or ROS1.
- You are well enough for treatment and surgery (ECOG 0–1) and have acceptable blood counts, liver, kidney, and heart/lung function.
- You can provide enough tumor tissue for biomarker testing and you sign the consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This trial tests whether giving a drug called Toripalimab after surgery can help prevent early-stage non-squamous non-small cell lung cancer from coming back. It is for people whose tumors have high-risk features and PD-L1 levels of at least 1%.
This trial tests whether combining two immunotherapy drugs (which help your immune system fight cancer) with a type of precisely targeted radiation (SBRT) is safe and effective for people with early-stage non-small cell lung cancer. If you qualify, you might receive a treatment that could boost your body's ability to destroy cancer cells.
This trial tests whether combining radiation, an immunotherapy drug (toripalimab), and chemotherapy before surgery can help shrink tumors and improve outcomes in people with resectable stage II to III non-small cell lung cancer. It aims to see if this approach works better than standard chemotherapy alone.
This trial compares two different drug combinations given before surgery for stage II-III non-small cell lung cancer (NSCLC). Both combinations include chemotherapy, and one also includes a newer type of immunotherapy. The goal is to see which approach shrinks tumors more effectively before surgery.
This trial tests an investigational drug called JSKN016 given before surgery to shrink non-small cell lung cancer tumors and improve outcomes. The goal is to see if this pre-treatment is safe and effective for patients with stage II-III disease that can be surgically removed.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.